Screening systems and methods for hpv-associated cervical disease

A method of detecting cervical disease, comprising:

• contacting a biological sample obtained from a patient with a plurality of binding agents, the plurality of binding agents specific to:
• a human papillomavirus (HPV) oncoprotein from each of three or more high-risk HPV (hr-HPV) isoforms, the HPV oncoprotein comprising at least one of HPV E7 or HPV E6, the three or more hr-HPV isoforms comprising at least one of HPV16, HPV18, and HPV45;
• and
• one or more cytokeratins selected from the group comprising K4, K5, K6, K8, K13, K17, and K18;
• and
• measuring specific binding between the plurality of binding agents and each of the HPV oncoprotein and one or more cytokeratins to determine levels of the HPV oncoprotein and one or more cytokeratins in the biological sample.

A point-of-care device for detecting cervical disease in a biological sample, comprising:

• a disposable cartridge having a chromatographic membrane formed of nitrocellulose, silica, paper, micro-patterned silicon, or polymeric materials, the chromatographic membrane further conjugated with a plurality of binding agents specific to:
• at least one human papillomavirus (HPV) oncoprotein from three or more high-risk HPV (hr-HPV) isoforms;
• at least one independent prognostic indicator for cervical disease;
• and
• at least one independent indicator of sample viability.